retatrutide type 2 diabetes phase 2 trial results Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, conducted in the USA Lilly's triple agonist delivers up
Pay in 4 interest-free payments of $6.21 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 26 - Oct 31




![Anti-Glutathione Peroxidase 3/GPx-3 antibody [EPR22815-112] (ab256470)](https://content.abcam.com/products/images/glutathione-peroxidase-3-gpx-3-antibody-epr22815-112-ab256470--immunohistochemistry-formalin-pfa-fixed-paraffin-embedded-sections-img111206.jpg)




![Anti-Glutathione Peroxidase 3/GPx-3 antibody [EPR22815-112] - BSA and Azide free (ab256475)](https://content.abcam.com/products/images/glutathione-peroxidase-3-gpx-3-antibody-epr22815-112-bsa-and-azide-free-ab256475--immunohistochemistry-formalin-pfa-fixed-paraffin-embedded-sections-img107650.jpg)





![Glutathione Peroxidase 3/GPX3 Antibody [Unconjugated]](https://images.novusbio.com/images/af4199_human-mouse-rat-glutathione-peroxidase-3-affinity-purif-pab-immunohistochemistry-12122025932593.jpg)











